Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C

Haemophilia

Volumn 10, Issue 5, 2004, Pages 413-421

  Theodore, D ^a   Fried, M W ^a   Kleiner, D E ^b   Kroner, B L ^c   Goedert, J J ^b   Eyster, M E ^d   Faust, S P ^e   Sherman, K E ^f   Kessler, C M ^g   Francis, C ^g   Aledort, Louis M ^h  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c RTI INTERNATIONAL   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e Hemophilia of Georgia   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Haemophilia; Hepatitis C; Liver biopsy

Indexed keywords

ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR 8; FRESH FROZEN PLASMA; INTERFERON;

ASCITES; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; HEMIHEPATECTOMY; HEMOPHILIA A; HEMOSTASIS; HEPATIC ARTERY LIGATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAUNDICE; LAPAROTOMY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MEDICAL SPECIALIST; NEEDLE BIOPSY; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS TRANSMISSION;

BIOPSY; HEMOPHILIA A; HEPATITIS C, CHRONIC; HUMANS; LIVER;

EID: 4844230601     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00919.x     Document Type: Review

References (48)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
2. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47: 1-39.
3. Thomas DL, Vlahov D, Solomon L et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212-20.
4. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Publ Health 1996; 86: 655-61.
5. Donahue JG, Nelson KE, Munoz A et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991; 134: 1206-11.
6. Kumar A, Kulkarni R, Murray DL et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993; 41: 205-9.
7. Troisi CL, Hollinger FB, Hoots WK et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412-8.
8. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002, June 10-12, 2002. Hepatology 2002; 36: S3-20.
9. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241-6.
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
11. Yano M, Kumada H, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.
12. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
13. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
14. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
15. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.
16. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-400.
17. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993; 118: 96-8.
18. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med 1993; 118: 150-3.
19. Smith TP, Presson TL, Heneghan MA, Ryan JM. Transjugular biopsy of the liver in pediatric and adult patients using an 18-gauge automated core biopsy needle: a retrospective review of 410 consecutive procedures. AJR Am J Roentgenol 2003; 180: 167-72.
20. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
22. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
23. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
24. Goldin RD, Goldin JG, Burt AD et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25: 649-54.
25. Westin J, Lagging LM, Wejstal R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 183-7.
26. Bejarano PA, Koehler A, Sherman KE. Second opinion pathology in liver biopsy interpretation. Am J Gastroenterol 2001; 96: 3158-64.
27. National Institutes of Health Consensus Development Conference Panel statement. Management of hepatitis C. Hepatology 1997; 26: 2S-10S.
28. Aledort LM, Levine PH, Hilgartner M et al. A study of liver biopsies and liver disease among hemophiliacs. Blood 1985; 66: 367-72.
29. Lee CA. Investigation of chronic hepatitis C infection in individuals with haemophilia. Br J Haematol 1997; 96: 425-6.
30. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-41.
31. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993; 38: 1480-4.
32. Perez-Olmeda M, Nunez M, Romero M et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. Aids 2003; 17: 1023-8.
33. Fried MW. Management of hepatitis C in the hemophilia patient. Am J Med 1999; 107: 85S-9S.
34. Makris M, Preston FE. Liver biopsy in haemophilia. Br J Haematol 1997; 97: 689-90.
35. Wong VS, Baglin T, Beacham E, Wight DD, Petrik J, Alexander GJ. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus. Br J Haematol 1997; 97: 343-7.
36. Venkataramani A, Behling C, Rond R, Glass C, Lyche K. Liver biopsies in adult hemophiliacs with hepatitis C: a United States center's experience. Am J Gastroenterol 2000; 95: 2374-6.
37. McMahon C, Pilkington R, Shea EO, Kelleher D, Smith OP. Liver biopsy in Irish hepatitis C-infected patients with inherited bleeding disorders. Br J Haematol 2000; 109: 354-9.
38. DiMichele DM, Mirani G, Wilfredo Canchis P, Trost DW, Talal AH. Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. Haemophilia 2003; 9: 613-8.
39. van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis 1995; 15: 340-59.
40. Lethagen S, Widell A, Berntorp E, Verbaan H, Lindgren S. Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease. Br J Haematol 2001; 113: 87-93.
41. Shields PL, Mutimer DJ, Muir D et al. Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders. Br J Haematol 2000; 108: 254-8.
42. Adamowicz-Salach A, Pawelec K, Loch T, Zdziebowska-Pawi inverted question marknska A, Brojer E, Walewska-Zielecka B, Rokicka-Milewska R. Incidence and treatment of hepatitis C virus infection in children with haemophilia in Poland. Haemophilia 1999; 5: 436-40.
43. Farrell RJ, Smiddy PF, Pilkington RM et al. Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol 1999; 30: 580-7.
44. Fukuda Y, Nakano I, Katano Y et al. Assessment and treatment of liver disease in Japanese haemophilia patients. Haemophilia 1998; 4: 595-600.
45. Gupta R, Druy EM, Kessler CM. Safety and potential usefulness of liver biopsy in HIV-seropositive haemophiliacs employing a transjugular venous approach. Haemophilia 1997; 3: 201-4.
46. Ahmed MM, Mutimer DJ, Elias E et al. A combined management protocol for patients with coagulation disorders infected with hepatitis C virus. Br J Haematol 1996; 95: 383-8.
47. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746-52.
48. Hanley JP, Jarvis LM, Andrews J et al. Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non-invasive methods. Br J Haematol 1996; 94: 159-65.